SOLIGENIX, INC.
SNGXNasdaq
$0.36
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↓ -73.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.6M
Enterprise Value
$3.6M
P/E
—
P/S
—
P/B
1.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-354.5%
ROIC
-299.2%
Debt / Equity
—
Net Cash
—
Return 1Y
-73.6%
Company profile
Soligenix, Inc. focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions.
- CEO
- Christopher J. Schaber
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- New Jersey
- Website
- www.soligenix.com
Management & directors
- Schaber Christopher JCHAIRMAN, CEO AND PRESIDENT
Roles derived from SEC Form 4 filings.
Earnings
SNGX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.28↓ -71.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.4M | $824,268.00 | $948,911.00 | $839,359.00 | $119,371.00 | — |
| Gross profit | $538,498.00 | $95,628.00 | $398,089.00 | $97,311.00 | — | — |
| Operating income | -$18.6M | -$13.1M | -$14.2M | -$7.7M | -$9.4M | -$11.8M |
| Net income | -$17.7M | -$12.6M | -$13.8M | -$6.1M | -$8.3M | -$11.1M |
| Diluted EPS | -$0.64 | -$4.69 | -$4.81 | -$12.66 | -$4.98 | -$2.14 |
| Operating cash flow | -$11.5M | -$11.7M | -$12.6M | -$8.6M | -$8.4M | -$10.3M |
| Free cash flow | — | — | — | — | — | -$10.3M |
| Gross margin | 22.8% | 11.6% | 42.0% | 11.6% | — | — |
| Operating margin | -787.7% | -1589.2% | -1500.6% | -917.1% | -7907.7% | — |
| Net margin | -749.7% | -1522.7% | -1454.1% | -731.6% | -6925.1% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2,342.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.7M | -$1.9M | -$3.7M | -$3.0M | -$2.8M | -$2.6M | -$3.5M | -$2.9M |
| Net income | -$1.6M | -$1.7M | -$3.0M | -$3.0M | -$2.7M | -$2.5M | -$2.9M | -$2.8M |
| Diluted EPS | -$1.31 | -$0.78 | $0.02 | -$0.97 | -$0.82 | -$0.58 | $0.23 | -$0.28 |
| Operating cash flow | -$1.9M | -$2.9M | -$2.2M | -$1.8M | -$2.7M | -$2.9M | -$2.7M | -$2.4M |
| Free cash flow | — | — | — | — | — | -$2.9M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -74495.1% | — | — | — | — | — | — | — |
| Net margin | -70217.8% | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-02 | SCHABER CHRISTOPHER J· CHAIRMAN, CEO AND PRESIDENT | Buy | 15,132 | $1.32 | $19,999.96 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.